Case Report Cardiology Quality Improvement
Rethinking emergency department revisits in pregnant women: the role of pharmacist-led medication review

Rethinking emergency department revisits in pregnant women: the role of pharmacist-led medication review

Authors

Zainab Ahmed

Zainab Ahmed

Royal Melbourne Hospital, French Southern Territories

Corresponding

Published

July 22, 2025

Paper ID

PAP-000052

Status

Published

DOI

10.65712/tmj.test000310

Rethinking emergency department revisits in pregnant women: the role of pharmacist-led medication review

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around pharmacist-led medication review varies widely between centres. Methods: We conducted a pilot feasibility study across 9 centres between 2019 and 2025. Results: 3800 participants were included (median age 77 years). emergency department revisits occurred in 7% of the intervention group versus 34% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

emergency department revisits remains a leading cause of avoidable harm among pregnant women. Earlier studies of pharmacist-led medication review were small or single-centre.

emergency department revisits remains a leading cause of avoidable harm among pregnant women. The cost of emergency department revisits to health systems is substantial. Practice around pharmacist-led medication review varies widely between centres.

Guidelines make only a weak recommendation on pharmacist-led medication review. The cost of emergency department revisits to health systems is substantial.

The cost of emergency department revisits to health systems is substantial. Practice around pharmacist-led medication review varies widely between centres. emergency department revisits remains a leading cause of avoidable harm among pregnant women.

Discussion

Residual confounding cannot be excluded. These findings suggest that pharmacist-led medication review is associated with better emergency department revisits in pregnant women. Implementation will depend on staffing, cost and local protocols.

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. Future work should test pharmacist-led medication review in a pragmatic multicentre trial.

Implementation will depend on staffing, cost and local protocols. These findings suggest that pharmacist-led medication review is associated with better emergency department revisits in pregnant women. Future work should test pharmacist-led medication review in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.

Conclusions

Pharmacist-led medication review may be offered for pregnant women to improve emergency department revisits.

References

1. Nakamura H, Schmidt L, et al. SGLT2 inhibitors and ventilator-free days. Pediatrics. 2025;224(7):509-1067.

2. Kaur G, Moreau H, et al. An enhanced recovery pathway and time to diagnosis. N Engl J Med. 2015;56(12):505-1693.

3. Rahman R, Silva O, et al. Home-based cardiac rehabilitation and patient satisfaction. BMJ. 2023;316(2):584-1557.

4. Zhang L, Larsen N, et al. Early mobilisation and falls. Crit Care Med. 2022;50(10):655-1578.

5. Volkov B, Ibrahim P, et al. An antibiotic stewardship programme and patient satisfaction. N Engl J Med. 2018;146(2):176-1441.

6. Ahmed Y, Andersen P, et al. Delayed cord clamping and ventilator-free days. Lancet. 2014;350(7):407-1326.

7. Patel X, Osei X, et al. Continuous glucose monitoring and time to diagnosis. Diabetes Care. 2024;189(5):112-1645.

Appendices

Supplementary tables are available on request.

Materials and Methods

The primary outcome was emergency department revisits, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.

Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.

Eligible participants were pregnant women. Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 8 centres between 2015 and 2023.

Results

Serious adverse events were rare and similar between groups. emergency department revisits occurred in 12% of the intervention group versus 28% of controls. Effects were consistent across prespecified subgroups. emergency department revisits occurred in 9% of the intervention group versus 21% of controls.

278 participants were included (median age 34 years). 308 participants were included (median age 73 years). emergency department revisits occurred in 16% of the intervention group versus 14% of controls. Effects were consistent across prespecified subgroups.

GroupnEvents
Centre A41745
Age ≥ 6568916
Centre A75969
Centre B335102
Control48063
Control19836
Age ≥ 6578226
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for emergency department revisits
Shown for pregnant women; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Change in emergency department revisits
Shown for pregnant women; error bars are 95% confidence intervals.

emergency department revisits occurred in 12% of the intervention group versus 12% of controls. The adjusted odds ratio was 0.75 (95% CI 0.42 to 0.96).